1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. ReGen Therapeutics Acquires Sciencom

M&A Deal Summary

ReGen Therapeutics Acquires Sciencom

On October 19, 2004, ReGen Therapeutics acquired life science company Sciencom

Acquisition Highlights
  • This is ReGen Therapeutics’ 2nd transaction in the Life Science sector.
  • This is ReGen Therapeutics’ 2nd transaction in the United Kingdom.

M&A Deal Summary
Date 2004-10-19
Target Sciencom
Sector Life Science
Buyer(s) ReGen Therapeutics
Deal Type Add-on Acquisition

Target

Sciencom

United Kingdom
Sciencom Ltd. is a private company, which is developing an important new use for zolpidem, a long-established drug, currently marketed for the treatment of insomnia. The new use relates to a novel application of zolpidem for the treatment of ‘brain dormancy/diaschisis’ (the ‘Application’) and Sciencom has filed patent application in this regard.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ReGen Therapeutics

London, United Kingdom
Category Company
Founded 1998
Sector Life Science
DESCRIPTION

ReGen Therapeutics Ltd. is a Company developing a treatment for Alzheimer's Disease. Company develop Colostrinin, a proline-rich polypeptide complex derived from mammalian colostrum.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: United Kingdom M&A 2 of 2
Year: 2004 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2004-10-19 Guildford Clinical Pharmacology Unit

Guildford, United Kingdom

Guildford Clinical Pharmacology Unit Limited is a contract research organisation (‘CRO’). The key features of its business are innovation in measuring pain and motility of the gastrointestinal system, its hospital site and an international list of clients.

Buy -
Mergr

Solution for

Product

Company

Legal